Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

Sex: All

Ages: 2 Years – 44 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 255

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Summary

The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo injections monthly for the duration of the study or until they are diagnosed with either stage 2 or stage 3 Type 1 Diabetes * Visit a study clinic every 6 months for Oral Glucose Tolerance Tests (OGTTs) and other tests until the end of the study

Eligibility Criteria

Inclusion Criteria: 1. Willing to provide informed consent or have a parent or legal guardians provide informed consent when the participant is \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07683026). StuddyBuddy aggregates publicly available trial information.